Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas
Sponsor: Novartis Pharmaceuticals
This PHASE1 trial investigates Advanced Soft Tissue Sarcoma and Locally Advanced Angiosarcoma and is currently completed. Novartis Pharmaceuticals leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Jan 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .